Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Valentina Garibotto
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability to understand the clinical trial and give an informed consent
Clinical diagnosis of prodromal AD, or mild or moderate AD
Ability to undergo neurocognitive assessment at baseline visit, alone or accompanied by a caregiver
Amyloid PET scan positivity
Ability to follow the 5-days RT regiment, alone or accompanied by a caregiver
You may not be if
Inclusion in another disease modifying clinical trial
Previous therapeutic brain irradiation
Evidence of vascular cognitive impairment on Magnetic Resonance Imaging (MRI) (Fazekas score \>1 and Wahlund score \>=10/30)
Oncologic disease (excluding skin cancer) active or in remission from less than 5 years
Evidence of substance abuse (alcohol and/or other drugs) with a dependence during the previous 12 months (DSM-IV criteria)
Presence of subdural hygroma's, subdural hematomas or hydrocephalus
Significant psychiatric comorbidity as assessed during the clinical evaluation by the neurologist/geriatrician in charge
Active or recent (within 3 months) cerebral infection/haemorrhage
Immunocompromised status
Prior history of seizure
Dermatological skin disease of the scalp
Women who are pregnant or breast feeding or who intend to become pregnant during the course of the study;
Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases;
